Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. Issue 5 (July 2018)

• Record Type: Journal Article
• Authors: Todesco, Eve; Mazzola, Alessandra; Akhavan, Sepideh; Abravanel, Florence; Poynard, Thierry; Roque-Afonso, Anne-Marie; Peytavin, Gilles; Marcelin, Anne-Geneviève; Calmus, Yvon; Lecuyer, Lucien; Guillemain, Romain; Conti, Filomena
• Is Part Of: Antiviral therapy. Volume 23:Issue 5(2018)
• Page Start: 463
• Page End: 465
• Publication Date: 2018-07
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3227
• Languages: English
• ISSNs: 1359-6535

Abstract

Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.